Financial statements Naturalantibody
Balance sheet data of NATURALANTIBODY
|
Year
|
2020
|
2022
|
2023
|
|---|---|---|---|
| Total assets | 3 192 003,29 | 3 839 886,74 | 2 902 249,17 |
| A. Fixed assets | 0,00 | 420 145,53 | 289 351,68 |
| B. Current assets | 3 192 003,29 | 3 419 741,21 | 2 612 897,49 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 |
| Total liabilities | 3 192 003,29 | 3 839 886,74 | 2 902 249,17 |
| A. Equity | 2 747 642,52 | 1 618 412,07 | 2 209 025,24 |
| B. Liabilities and provisions for liabilities | 444 360,77 | 2 221 474,67 | 693 223,93 |
| I. Long-term liabilities | 0,00 | 0,00 | 0,00 |
| II. Short-term liabilities | 444 360,77 | 2 221 474,67 | 539 324,83 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.